Lack of immunogenicity of incobotulinumtoxinA in pediatrics: A pooled analysis
Objective: To present pooled data analyses of the immunogenicity of incobotulinumtoxinA (INCO) in pediatrics. Background: BotulinumtoxinA (BoNT-A) is used to treat several chronic pediatric conditions,…Pain and Disability Outcomes in Hemiparetic Patients With Post-Stroke Spasticity: Exploratory Analysis of the ASPIRE Study
Objective: To assess measures of pain and functional impairment in hemiparetic patients with post-stroke spasticity (PSS) treated with onabotulinumtoxinA (onabotA) from the Adult Spasticity International…Treating Upper Limb Spasticity With OnabotulinumtoxinA: Subgroup Analysis of US Practice Patterns From the ASPIRE Study
Objective: To examine onabotulinumtoxinA (onabotA) treatment utilization patterns in the United States (US) for pronated forearm and intrinsic plus hand postures in patients with upper…Efficacy and safety of incobotulinumtoxinA for upper- or combined upper- and lower-limb spasticity in children/adolescents with cerebral palsy: the XARA study
Objective: To assess the efficacy/safety of incobotulinumtoxinA for upper- and combined upper-/lower-limb spasticity in ambulant and non-ambulant children/adolescents with cerebral palsy (CP). Background: Spastic CP…Absence of neutralizing antibody formation during incobotulinumtoxinA treatment of spasticity in botulinum toxin-naïve children with cerebral palsy: pooled analysis of Phase 3 studies
Objective: To investigate neutralizing antibody (NAb) formation in three large Phase 3 studies with incobotulinumtoxinA, a botulinum neurotoxin type A (BoNT-A) with no complexing proteins,…Assessing effectiveness of abobotulinumtoxinA injections for adult lower limb spasticity in routine clinical practice: The ongoing AboLiSh study
Objective: The aim of this ongoing observational study is to systematically assess goal attainment over 16 months in patients treated with ≥1 abobotulinumtoxinA (aboBoNT-A) injection(s)…OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study
Objective: Examine onabotulinumtoxinA utilization in patients with upper limb (UL) and lower limb (LL) spasticity from the Adult Spasticity International Registry (ASPIRE) study to gain…Disparities in Access to Spasticity Chemodenervation Specialists in the United States: a National Analysis of Medicare Data
Objective: To explore the variations in access to spasticity chemodenervation specialists across several geographical, ethnic, racial, and population density factors. Background: Equity in access to…Neutralizing Antibody Conversion With OnabotulinumtoxinA From Global Studies Across Multiple Indications With A Focus On Movement Disorders: A Meta-Analysis
Objective: A meta-analysis of clinical trial data across 10 indications for onabotulinumtoxinA was performed to assess incidence of neutralizing antibody (nAb) formation with a focus…COMPARISON OF ELECTROPHYSIOLOGIC AND ULTRASOUND GUIDANCE FOR ONABOTULINUM TOXIN-A INJECTIONS IN FOCAL UPPER EXTREMITY SPASTICITY AND DYSTONIA
Objective: To investigate two targeting techniques for onabotulinum toxin-A (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity: guidance with electrical…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 6
- Next Page »